Biallelic TP53 alterations tend to occur early in MDS and AML development to promote survival and gradually become dominant clones that harbor fewer co-mutations (up to 40% of cases have no other driver mutations) [10]. The gene discussed is TP53; the disease is myelodysplastic syndrome.